Eterna Therapeutics Statistics
Share Statistics
Eterna Therapeutics has 51.37M shares outstanding. The number of shares has increased by 849.57% in one year.
| Shares Outstanding | 51.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 849.52% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.88M |
| Failed to Deliver (FTD) Shares | 5.44K |
| FTD / Avg. Volume | 0.64% |
Short Selling Information
The latest short interest is 44.46K, so 0.09% of the outstanding shares have been sold short.
| Short Interest | 44.46K |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.09% |
| Short Ratio (days to cover) | 1.07 |
Valuation Ratios
The PE ratio is -0.44 and the forward PE ratio is -0.11.
| PE Ratio | -0.44 |
| Forward PE | -0.11 |
| PS Ratio | 140.66 |
| Forward PS | 0.2 |
| PB Ratio | 4.28 |
| P/FCF Ratio | -0.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Eterna Therapeutics Inc. has an Enterprise Value (EV) of 43.83M.
| EV / Earnings | -2.02 |
| EV / Sales | 644.61 |
| EV / EBITDA | -2.2 |
| EV / EBIT | -2.07 |
| EV / FCF | -2.15 |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 4.03.
| Current Ratio | 1.46 |
| Quick Ratio | 1.46 |
| Debt / Equity | 4.03 |
| Total Debt / Capitalization | 80.1 |
| Cash Flow / Debt | -2.27 |
| Interest Coverage | -34.42 |
Financial Efficiency
Return on equity (ROE) is -9.7% and return on capital (ROIC) is -47.94%.
| Return on Equity (ROE) | -9.7% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -47.94% |
| Revenue Per Employee | 8.50K |
| Profits Per Employee | -2.71M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -3.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -82.01% in the last 52 weeks. The beta is 7.77, so Eterna Therapeutics 's price volatility has been higher than the market average.
| Beta | 7.77 |
| 52-Week Price Change | -82.01% |
| 50-Day Moving Average | 0.6 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 42.6 |
| Average Volume (20 Days) | 856.93K |
Income Statement
In the last 12 months, Eterna Therapeutics had revenue of 68.00K and earned -21.67M in profits. Earnings per share was -4.08.
| Revenue | 68.00K |
| Gross Profit | -168.00K |
| Operating Income | -21.14M |
| Net Income | -21.67M |
| EBITDA | -19.93M |
| EBIT | -21.14M |
| Earnings Per Share (EPS) | -4.08 |
Balance Sheet
The company has 7.58M in cash and 41.84M in debt, giving a net cash position of -34.27M.
| Cash & Cash Equivalents | 7.58M |
| Total Debt | 41.84M |
| Net Cash | -34.27M |
| Retained Earnings | -186.98M |
| Total Assets | 7.72M |
| Working Capital | -5.22M |
Cash Flow
In the last 12 months, operating cash flow was -20.41M and capital expenditures -19.00K, giving a free cash flow of -20.43M.
| Operating Cash Flow | -20.41M |
| Capital Expenditures | -19.00K |
| Free Cash Flow | -20.43M |
| FCF Per Share | -3.84 |
Margins
Gross margin is -24.71K%, with operating and profit margins of -3.11M% and -3.19M%.
| Gross Margin | -24.71K% |
| Operating Margin | -3.11M% |
| Pretax Margin | -3.19M% |
| Profit Margin | -3.19M% |
| EBITDA Margin | -29.31K% |
| EBIT Margin | -31.08K% |
| FCF Margin | -30.04K% |
Dividends & Yields
ERNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1200% |
| FCF Yield | -115.25% |
Analyst Forecast
Currently there are no analyst rating for ERNA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 17, 2022. It was a backward split with a ratio of 1:20.
| Last Split Date | Oct 17, 2022 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -59.19 |
| Piotroski F-Score | 3 |